drugset
drugset / Trial / NCT07448077

Short-course Radiotherapy in TNT Combined With Enlonstobart for pMMR LARC

NCT07448077 ↗

Phase 2 Not yet recruiting 128 enrolled Hebei Medical University Fourth Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

Efficacy and safety of short-course radiotherapy in total neoadjuvant therapy combined with enlonstobart for pMMR locally advanced rectal cancer

Timeline

Start
2026-03-01
Primary completion
2026-03-01
Completion
2030-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 825 mg/m2 —
Subject Capecitabine Small molecule 1000 mg/m2 —
Subject Enlonstobart Monoclonal antibody 200 mg Intravenous
Background Oxaliplatin Small molecule 130 mg/m2 Intravenous

Indications

No indication recorded.